Viberzi is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) [1]. It is an oral bile acid sequestrant [2].
How does Viberzi work?
Viberzi contains the active ingredient eluxadoline [1]. Eluxadoline is a mixed mu-opioid receptor agonist and delta-opioid receptor antagonist that acts locally on the gut. By binding to these receptors in the gastrointestinal tract, it reduces the frequency of bowel movements and decreases abdominal pain associated with IBS-D [2].
What is the difference between Viberzi and other IBS-D treatments?
Viberzi's mechanism of action, targeting opioid receptors locally in the gut, differentiates it from other IBS-D treatments. For instance, bile acid sequestrants work by binding to bile acids in the intestine, preventing them from irritating the colon [2].
When does Viberzi's patent expire?
Information on Viberzi's patent expiry can be found through resources like DrugPatentWatch.com [3]. Understanding patent exclusivity is crucial for anticipating potential generic competition.
What are the potential side effects of Viberzi?
Common side effects of Viberzi include constipation, nausea, abdominal pain, and upper respiratory tract infection [1]. A serious but rare side effect is pancreatitis, particularly in patients who have had their spleen removed [1]. Patients with a history of sphincter of Oddi dysfunction are also at increased risk [1].
Are there any specific patient populations who should avoid Viberzi?
Viberzi is contraindicated in patients who have had their spleen removed [1]. It should also be used with caution in patients with a history of sphincter of Oddi dysfunction or pancreatic issues [1].
What is the typical cost of Viberzi?
The cost of Viberzi can vary depending on insurance coverage and pharmacy pricing. Patient assistance programs may be available to help reduce out-of-pocket expenses [4].
Who manufactures Viberzi?
Viberzi is manufactured by AbbVie Inc. [1].
What clinical data supports Viberzi's use?
Clinical trials have demonstrated that Viberzi is effective in reducing both bowel urgency and abdominal pain in patients with IBS-D [2].
What are the risks associated with stopping Viberzi?
Stopping Viberzi treatment may lead to a return of IBS-D symptoms [2].
---
Sources:
[1] https://www.viberzi.com/
[2] https://www.drugs.com/viberzi.html
[3] https://drugpatentwatch.com/
[4] https://www.rxlist.com/viberzi-drug.htm